GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence
GLP-1RA therapy after MI or stroke in T2D was associated with substantially lower risks of MACE, cardiovascular and all-cause death in real-world practice. Utilization remained low, particularly among women and older adults, underscoring the need for broader and more equitable implementation in secondary prevention.
Authors
- Gleb Donin (ORCID: https://orcid.org/0000-0003-3786-5932)
- Petra Šedová (ORCID: https://orcid.org/0000-0002-1379-0203)
- Simona Littnerová
- Petr Kala (ORCID: https://orcid.org/0000-0002-4416-9065)
- Robert Mikulík (ORCID: https://orcid.org/0000-0002-7458-5166)
- Julia Anna Kent
- Virend Kristen Somers (ORCID: https://orcid.org/0000-0003-4045-4341)
- Michal Vráblík (ORCID: https://orcid.org/0000-0002-7226-1926)
- Jiri Jarkovsky
- R Brown
- Ales Tichopad
- Aleš Tomek
- Petr Ošťádal
Institutions
- Mayo Clinic (US)
- Tomas Bata University in Zlín (CZ)
- Charles University (CZ)
- Masaryk University (CZ)
- University Hospital in Motol (CZ)
- Mayo Clinic in Arizona (US)
- General University Hospital in Prague (CZ)
- Czech Technical University in Prague (CZ)
- PRA Health Sciences (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1093/eurjpc/zwag002
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 61.46